摘要
目的 探讨地西他滨治疗骨髓增生异常综合征(MDS)的疗效及对钙黏附分子1(CDH1)和P15甲基化水平、生存质量的影响.方法 选择75例MDS患者,按治疗方法分为对照组(37例,CAG化疗)和观察组(38例,CAG化疗+地西他滨).比较两组临床疗效、血小板计数、血红蛋白、白细胞计数、CDH1、P15甲基化水平、生存质量、不良反应发生率.结果 观察组客观缓解率高于对照组(P＜0.05).两组不良反应总发生率比较差异无显著性(P＞0.05).与治疗前比较,治疗后两组血小板计数、血红蛋白、白细胞计数升高;CDH1、P15甲基化水平、情绪功能、伴随情况、主要症状、认知程度、满意程度评分降低;且观察组较对照组变化更显著(P＜0.05).结论 地西他滨治疗MDS疗效显著,下调体内甲基化水平,改善生存质量;且不会增加不良反应发生风险.
Abstract
Aim To investigate the efficacy of decitabine in the treatment of myelodysplastic syndrome(MDS)and its effects on the methylation level of calcium adhesion molecule 1(CDH1)and P15 and quality of life.Methods Seventy-five MDS patients were randomly divided into control group(37 cases with CAG chemotherapy)and observation group(38 cases with CAG chemotherapy+decitabine).The clinical efficacy,platelet count,hemoglobin,white blood cell count,methylation levels of CDH1 and P15,quality of life and incidence of adverse reactions were compared between the two groups.Results The objective remis-sion rate of observation group was higher than that of control group(P＜0.05).There was no significant difference in the total inci-dence of adverse reactions between the two groups(P＞0.05).Compared with before treatment,the platelet count,hemoglobin,and white blood cell count increased in both groups after treatment;the methylation levels of CDH1 and P15,emotional function,accompa-nying conditions,main symptoms,cognitive level,and satisfaction score decrease;and the changes in the observation group were more significant than those in the control group(P＜0.05).Conclusion Decitabine is effective in the treatment of MDS to downregu-late the methylation level in vivo and improve the quality of life.It does not increase the risk of adverse reactions,and has a high clinical reference value.
维普
万方数据